Piper Sandler Maintains Neutral on OncoCyte, Lowers Price Target to $3.5
Portfolio Pulse from jenniferd'souza@benzinga.com
Piper Sandler analyst David Westenberg has maintained a Neutral rating on OncoCyte (NASDAQ:OCX) and lowered the price target from $6 to $3.5.
August 15, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on OncoCyte and lowered the price target from $6 to $3.5.
The lowering of the price target by Piper Sandler from $6 to $3.5 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on OncoCyte's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100